AbstractSteady-state analysis of nucleotide-binding sites on rat liver plasma membranes was carried out using 3H-labelled ATP as radioligand under complete inhibition of ecto-ATPase activity by excess EDTA. Binding of [3H]ATP to the membranes is saturable, reversible and apparently involves one population of specific binding sites with Kd of about 90 nM and binding capacity (Bmax) of 15 pmol/mg protein. A broad spectrum of purinergic agonists and antagonists was examined as potential inhibitors of the measured binding. The displacement studies showed the following rank order of inhibitory potency for [3H]ATP-binding sites (pIC50 values in parentheses): ATPγS (7.49)>2-MeSATP (7.18)>ATP (6.91)>ADPβS (6.64)≥ADP (6.56)≫RB2 (6.14)≫suramin (5.40)...
Study of P2-purinoceptor subtypes has been difficult due to the lack of potent and selective ligands...
UTP is a potent full agonist at both the human P2Y4 (hP2Y4) and rat P2Y4 (rP2Y4) receptor. In contra...
AbstractBased on the capacity to increase IP3 (inositol 1,4,5-trisphosphate), P2 purinergic agonists...
AbstractInhibitory effects of various purinergic compounds on the Mg2+-dependent enzymatic hydrolysi...
AbstractUsing ATPα35S as radioligand, we have detected the presence of specific purinoceptors on hum...
AbstractHormonal regulation of phospholipase D (PLD) was studied in isolated rat liver plasma membra...
Analogs of ATP and ADP produce a guanine nucleotide-dependent activation of phospholipase C in turke...
AbstractP1,P4-Diadenosine 5′-tetraphosphate (Ap4A) acts as an extracellular modulator through its in...
1) The pharmacological actions of adenine and uracil nucleotides are reviewed. The current knowledge...
The effects of oxidized ATP (oATP) on responses triggered by extracellular adenosine 5'-triphosphate...
AbstractExtracellular ATP regulates many hepatic functions by stimulating purinergic receptors. Only...
1. We reported previously that bisphosphate derivatives of adenosine are antagonists of the P2Y(1) r...
1. Analogues of adenine nucleotides inhibited beta-adrenoceptor-stimulated cyclic AMP accumulation i...
Pharmacological properties of the human P2Y1 receptor trans-fected in Jurkat cells and of the endoge...
The structure-activity relationships for a variety of adenine nucleotide analogues at P2x- and P2Y-p...
Study of P2-purinoceptor subtypes has been difficult due to the lack of potent and selective ligands...
UTP is a potent full agonist at both the human P2Y4 (hP2Y4) and rat P2Y4 (rP2Y4) receptor. In contra...
AbstractBased on the capacity to increase IP3 (inositol 1,4,5-trisphosphate), P2 purinergic agonists...
AbstractInhibitory effects of various purinergic compounds on the Mg2+-dependent enzymatic hydrolysi...
AbstractUsing ATPα35S as radioligand, we have detected the presence of specific purinoceptors on hum...
AbstractHormonal regulation of phospholipase D (PLD) was studied in isolated rat liver plasma membra...
Analogs of ATP and ADP produce a guanine nucleotide-dependent activation of phospholipase C in turke...
AbstractP1,P4-Diadenosine 5′-tetraphosphate (Ap4A) acts as an extracellular modulator through its in...
1) The pharmacological actions of adenine and uracil nucleotides are reviewed. The current knowledge...
The effects of oxidized ATP (oATP) on responses triggered by extracellular adenosine 5'-triphosphate...
AbstractExtracellular ATP regulates many hepatic functions by stimulating purinergic receptors. Only...
1. We reported previously that bisphosphate derivatives of adenosine are antagonists of the P2Y(1) r...
1. Analogues of adenine nucleotides inhibited beta-adrenoceptor-stimulated cyclic AMP accumulation i...
Pharmacological properties of the human P2Y1 receptor trans-fected in Jurkat cells and of the endoge...
The structure-activity relationships for a variety of adenine nucleotide analogues at P2x- and P2Y-p...
Study of P2-purinoceptor subtypes has been difficult due to the lack of potent and selective ligands...
UTP is a potent full agonist at both the human P2Y4 (hP2Y4) and rat P2Y4 (rP2Y4) receptor. In contra...
AbstractBased on the capacity to increase IP3 (inositol 1,4,5-trisphosphate), P2 purinergic agonists...